Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Go Back to All Clinical Trials

Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Advanced Solid Tumors
Age: Between 18 Year(s) - 99 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. 18 years of age or older
2. Histologically or cytologically documented malignant solid tumor diseases that is locally advanced or metastatic
3. Exhausted available standard of care systemic therapy or should not be candidates for such available therapy

You may not be eligible for this study if the following are true:

1. Have an ongoing or active infection that requires intravenous (IV) anti-infective therapy within one week before receiving the first dose of AMG 305
2. Evidence of new or growing central nervous system (CNS) metastases, leptomeningeal disease, or spinal cord compression.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies